On the afternoon of March 22, Yin Li, Secretary of the CPC Beijing Municipal Committee, met with heads of multinational pharmaceutical companies attending the International Pharmaceutical Innovation Forum 2025 (IPIF 2025). Yin Yong, Deputy Secretary of the CPC Beijing Municipal Committee and Mayor of Beijing; Bi Jingquan, Vice Chairman of the Economic Committee of the Chinese People’s Political Consultative Conference (CPPCC) and Executive Chairman of the China Center for International Economic Exchanges (CCIEE); and You Jun, Deputy Secretary and Head of the Organization Department of the CPC Beijing Municipal Committee, also attended the meeting.
Yin Li noted that the Chinese government has always prioritized people’s health, and is committed to advancing the Healthy China initiative and fostering a global community of health for all. With continuous economic and social development and rising household incomes, public demand for healthcare services is increasing, creating vast opportunities for pharmaceutical enterprises. Currently, Beijing’s key health indicators have met advanced international standards. The city’s pharmaceutical and healthcare industry has surpassed RMB one trillion in output value. Beijing, with abundant resources in education, science and technology, and talent, has produced numerous pharmaceutical innovation outcomes, accompanied by robust corporate investment, a continuously improving business environment, and increasing openness to the world. Looking ahead, Beijing aims to establish a globally influential pharmaceutical and healthcare industry cluster. The city will deepen cooperation with all stakeholders, enhance pharmaceutical innovation, and work on innovative drugs and advanced therapies for chronic diseases, rare diseases, cancer, and degenerative conditions. It will also advance cutting-edge technologies such as gene therapy and cell therapy, accelerate digital healthcare development, and broaden AI application in medical and health services. Beijing will foster emerging healthcare services, including internet-based healthcare, mobile diagnosis and treatment, and intelligent medical engineering. The city will continue to strengthen international exchanges and cooperation in the healthcare sector, facilitating experience-sharing in public health, clinical diagnosis and treatment, industry regulation, and other fields. Yin Li welcomed multinational pharmaceutical companies to expand their presence in Beijing, leverage the city’s policy of piloting reforms, and introduce more innovative medicines to the Chinese market through Beijing. The city will further facilitate market access, strengthen intellectual property protection, and provide a world-class business environment to support the growth of multinational pharmaceutical enterprises.
Business executives from multinational pharmaceutical companies, including Albert Bourla, Chairman and CEO of Pfizer, and André Hoffmann, Vice Chairman of Roche Holding AG and representative of the founding family, highlighted China’s remarkable progress in the pharmaceutical and healthcare sector. They commended Beijing’s world-class business environment, which offers a robust foundation for corporate growth. They expressed their commitment to supporting the Healthy China initiative through greater cooperation with Beijing, increased investment and a broader business presence in the city. These efforts will contribute to Beijing’s high-quality development while improving public health and well-being.
Attendees also include Beijing municipal leaders Jin Wei and Zhao Lei; Su Wei, Party Secretary of CCIEE; and Zeng Jin, Secretary General of the People’s Government of Beijing Municipality.
(Written by Qi Mengzhu, Fan Junsheng)
